These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
49. Capture of drug targets from live cells using a multipurpose immuno-chemo-proteomics tool. Saxena C; Bonacci TM; Huss KL; Bloem LJ; Higgs RE; Hale JE J Proteome Res; 2009 Aug; 8(8):3951-7. PubMed ID: 19537828 [TBL] [Abstract][Full Text] [Related]
50. Synthesis of bosutinib from 3-methoxy-4-hydroxybenzoic acid. Yin XJ; Xu GH; Sun X; Peng Y; Ji X; Jiang K; Li F Molecules; 2010 Jun; 15(6):4261-6. PubMed ID: 20657439 [TBL] [Abstract][Full Text] [Related]
51. Proteomic analysis of Nipponia nippon (ID#162). Oyanagi M; Kaneko K; Kaneko Y; Sasaki M; Nishida C; Matsuda Y; Mitsui T Anim Sci J; 2014 Aug; 85(8):814-32. PubMed ID: 24961376 [TBL] [Abstract][Full Text] [Related]
52. Proteomics-based strategies in kinase drug discovery. Bantscheff M; Hopf C; Kruse U; Drewes G Ernst Schering Found Symp Proc; 2007; (3):1-28. PubMed ID: 18512284 [TBL] [Abstract][Full Text] [Related]
57. Heme drives hemolysis-induced susceptibility to infection via disruption of phagocyte functions. Martins R; Maier J; Gorki AD; Huber KV; Sharif O; Starkl P; Saluzzo S; Quattrone F; Gawish R; Lakovits K; Aichinger MC; Radic-Sarikas B; Lardeau CH; Hladik A; Korosec A; Brown M; Vaahtomeri K; Duggan M; Kerjaschki D; Esterbauer H; Colinge J; Eisenbarth SC; Decker T; Bennett KL; Kubicek S; Sixt M; Superti-Furga G; Knapp S Nat Immunol; 2016 Dec; 17(12):1361-1372. PubMed ID: 27798618 [TBL] [Abstract][Full Text] [Related]
58. Target interaction profiling of midostaurin and its metabolites in neoplastic mast cells predicts distinct effects on activation and growth. Peter B; Winter GE; Blatt K; Bennett KL; Stefanzl G; Rix U; Eisenwort G; Hadzijusufovic E; Gridling M; Dutreix C; Hoermann G; Schwaab J; Radia D; Roesel J; Manley PW; Reiter A; Superti-Furga G; Valent P Leukemia; 2016 Feb; 30(2):464-72. PubMed ID: 26349526 [TBL] [Abstract][Full Text] [Related]
59. Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomics. Gridling M; Ficarro SB; Breitwieser FP; Song L; Parapatics K; Colinge J; Haura EB; Marto JA; Superti-Furga G; Bennett KL; Rix U Mol Cancer Ther; 2014 Nov; 13(11):2751-62. PubMed ID: 25189542 [TBL] [Abstract][Full Text] [Related]
60. A target-disease network model of second-generation BCR-ABL inhibitor action in Ph+ ALL. Rix U; Colinge J; Blatt K; Gridling M; Remsing Rix LL; Parapatics K; Cerny-Reiterer S; Burkard TR; Jäger U; Melo JV; Bennett KL; Valent P; Superti-Furga G PLoS One; 2013; 8(10):e77155. PubMed ID: 24130846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]